secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0001193125-22-172488
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Homology's pheNIX gene therapy trial for HMI-102 in PKU
--------------------------------------------------------------------------------

- FDA lifted clinical hold on pheNIX trial (HMI-102) for phenylketonuria; company resolved all issues from March 17, 2022 hold.
- Clinical hold related to elevated liver function tests, all resolved without hospitalizations.
- Protocol changes include steroid-sparing immunosuppression with tacrolimus and shorter steroid course.
- Company plans to provide program update in fall 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522172488/0001193125-22-172488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522172488/d358045d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-172488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer